KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Depreciation and Depletion (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Depreciation and Depletion data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 1.45% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $33.7 million, up 56.74%, while the annual FY2025 figure was $33.7 million, 56.74% up from the prior year.
  • Depreciation and Depletion reached $7.0 million in Q4 2025 per PCRX's latest filing, up from $6.9 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $16.2 million in Q4 2022 and bottomed at $2.9 million in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $6.1 million, with a median of $5.6 million recorded in 2021.
  • Peak YoY movement for Depreciation and Depletion: surged 200.0% in 2022, then tumbled 74.07% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $5.4 million in 2021, then soared by 200.0% to $16.2 million in 2022, then crashed by 74.07% to $4.2 million in 2023, then skyrocketed by 64.29% to $6.9 million in 2024, then grew by 1.45% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $7.0 million in Q4 2025, $6.9 million in Q3 2025, and $13.0 million in Q2 2025.